STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3638 by analyst upside · 2026-08-12
TMO
Thermo Fisher Scientific Inc
Healthcare · Market Cap $224B · P/E 32.5x
ANALYST PRICE TARGET
+4.4%
implied upside to consensus target
Current Price $605.0
Consensus Target $631.42
Bull Target $750.0
Bear Target $520.0
Analysts Covering 26
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
18
Hold
6
Sell
0
52-Week Low $435.27
52-Week High $643.99
YTD Return +2.3%
FUNDAMENTALS
Market Cap $224B
P/E Ratio (TTM) 32.5x
Forward P/E 22.0x
EPS (TTM) $18.59
PEG Ratio 1.96
Dividend Yield 0.31%
Revenue (TTM) $46.3B
Profit Margin 15.0%
52-WEEK RANGE
52-Week Low $435.27
52-Week High $643.99
Current Price $605.0
Bear Target $520.0
Bull Target $750.0
● Now $605.0 ● Target $631.42
TRADING DATA
Avg Volume 2.3M
YTD Return +2.3%
Analyst Count 26
Consensus Buy
Upside to Target +4.4%
Last Updated 2026-08-12

ANALYST SUMMARY

Thermo Fisher Scientific Inc (TMO) is currently trading at $605.0 with a Wall Street consensus price target of $631.42, implying potential upside of 4.4% over the next 12 months. 26 analysts currently cover TMO, with a consensus rating of Buy - 78% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $750.0, while the most cautious has a target of $520.0.

TMO operates in the Healthcare sector with a market capitalisation of $224B. The stock is up 2.3% year-to-date and is currently trading near the upper end of its 52-week range of $435.27 – $643.99.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TMO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler ● Initiated
Neutral 2026-06-11 14% win rate (7 calls)
HSBC ↓ Downgrade
Buy → Hold 2026-06-03 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-05-08 Building track record
Stifel - Reiterated
Buy → Buy 2026-04-24 Building track record
Baird - Reiterated
Outperform → Outperform 2026-04-24 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-04-14 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-04-06 Building track record
Citigroup - Reiterated
Buy → Buy 2026-01-30 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
61
out of 100
Coverage depth
25/30
Consensus clarity
22/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →